Nvidia has invested roughly $10.4 million in Generate Biomedicines through its venture arm, making it one of the semiconductor giant's top five holdings.
Generate, which went public in February, uses machine-learning models to design novel protein drugs targeting disease pathways traditional methods cannot reach; its lead candidate has advanced to phase 3 trials for severe asthma.
The company reported $516.6 million in cash as of Q1, estimated to sustain operations for roughly two years, though it posted a $61.7 million net loss that quarter.
What happened
Generate Biomedicines (GENB), a clinical-stage biotech using AI to design new protein drugs, is one of Nvidia's top five largest holdings through its venture arm NVentures. Nvidia has roughly $10.4 million invested in the company, which went public in February and is up more than 12% so far this year.
Why it matters
Generate uses proprietary machine-learning architectures—including its Chroma model—to engineer novel protein therapeutics from scratch, targeting disease pathways that traditional drug discovery struggles to reach. Its lead candidate GB-0895 has reached phase 3 trials for severe asthma and early-stage trials in COPD, with backing from Amgen providing institutional validation. Unlike single-drug developers, Generate can systematically generate dozens of clinical candidates across multiple therapeutic areas, spreading risk across numerous targets.
What to watch
Generate is a clinical-stage company with limited revenue ($7.2 million in Q1 from collaborations) and a net loss of $61.7 million for Q1, compared with $44.3 million a year earlier. It reported $516.6 million in cash as of Q1, estimated to last roughly two years at its current burn rate. Like all biotech companies, it faces the unpredictability of human biology and the risk of phase 2 and phase 3 trial failures due to unforeseen toxicity or lack of efficacy.
Ask the AI about this article →
Generate Biomedicines represents a convergence of artificial intelligence and drug discovery—an area where Nvidia, the dominant chip supplier for AI workloads, has made a strategic bet through its venture capital arm. By holding roughly $10.4 million in the biotech company, Nvidia signals confidence in computational approaches to protein engineering and validates the business model outside its core semiconductor business. The company's core technology, which uses proprietary machine-learning architectures like its Chroma model to design novel proteins from scratch rather than modifying existing compounds, appeals to investors because it diversifies risk across multiple therapeutic areas instead of betting on a single drug candidate.
However, Generate faces the structural challenges endemic to clinical-stage biotech: unpredictable human biology and steep capital requirements. Despite reporting Q1 revenue of $7.2 million from partnerships with Amgen and Nvidia, the company posted a net loss of $61.7 million that quarter—significantly worse than the $44.3 million loss a year earlier. With roughly two years of cash runway at current burn rates, Generate must either demonstrate clinical success in its phase 3 trials or secure additional funding to sustain development.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
AI system scaling has pushed interconnect requirements inside data centers from chips and boards up to racks…
Chinese large-model developer Z.ai says it can now support large-scale inference using roughly 100,000 domesti…
Analyst Ming-Chi Kuo says Nvidia has revived the Rubin CPX AI accelerator with a substantially redesigned arch…
Palantir Technologies stock has posted multi-year gains, including an 11x return over 3 years
Apple has escalated its legal battle against OpenAI, claiming in a new court filing that OpenAI is actively de…
Samsung Electronics has locked up as much as 70% of its memory production capacity under long-term supply agre…
